Advanced in Raynaud Phenomenon

Dr. Jerry A. Molitor

Rheumatology
Fairview Express Care
909 Fulton St Se, 
Minneapolis, MN 
Accepting New Patients
Advanced in Raynaud Phenomenon
Fairview Express Care
909 Fulton St Se, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jerry Molitor is a Rheumatologist in Minneapolis, Minnesota. Dr. Molitor is rated as an Advanced provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleroma, and Dermatomyositis. Dr. Molitor is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Raynaud Phenomenon.

Specialties
Rheumatology
Licenses
Internal Medicine in WA
Hospital Affiliations
M Health Fairview University Of Mn
Languages Spoken
English
German
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

FAIRVIEW EXPRESS CARE
909 Fulton St Se, Minneapolis, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological
Study Drug: Brentuximab vedotin
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

31 Total Publications

Dense fine speckled antinuclear antibody patterns: Clinical correlations and implications.
Dense fine speckled antinuclear antibody patterns: Clinical correlations and implications.
Journal: Current rheumatology research
Published: August 13, 2025
Similar Doctors
Advanced in Raynaud Phenomenon
Dr. Mayra G. Oberto-Medina
Rheumatology
Advanced in Raynaud Phenomenon
Dr. Mayra G. Oberto-Medina
Rheumatology

North Memorial Health Care

3300 Oakdale Ave N, 
Robbinsdale, MN 
 (5.6 miles away)
763-520-5200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mayra Oberto-Medina is a Rheumatologist in Robbinsdale, Minnesota. Dr. Oberto-Medina is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. Her top areas of expertise are Osteoporosis, Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, and Psoriasis. Dr. Oberto-Medina is currently accepting new patients.

Advanced in Raynaud Phenomenon
Dr. Marty T. Mertens
Rheumatology
Advanced in Raynaud Phenomenon
Dr. Marty T. Mertens
Rheumatology

Infinite Health Collaborative, PA

4040 Radio Dr, 
Woodbury, MN 
 (14.8 miles away)
651-438-8807
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marty Mertens is a Rheumatologist in Woodbury, Minnesota. Dr. Mertens is rated as an Advanced provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), Ankylosing Spondylitis, and Reactive Arthritis. Dr. Mertens is currently accepting new patients.

Advanced in Raynaud Phenomenon
Dr. Sou-pan P. Wu
Rheumatology
Advanced in Raynaud Phenomenon
Dr. Sou-pan P. Wu
Rheumatology

Infinite Health Collaborative, PA

4040 Radio Dr, 
Woodbury, MN 
 (14.8 miles away)
651-438-8807
Languages Spoken:
English, Mandarin, Taiwanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Sou-pan Wu is a Rheumatologist in Woodbury, Minnesota. Dr. Wu is rated as an Advanced provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), and Temporal Arteritis. Dr. Wu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molitor's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile